Need to keep on high of the science and politics driving biotech right this moment? Enroll to get our biotech e-newsletter in your inbox.
Good morning. It’s the second week of the Trump administration and the information popping out of D.C. is unending. Learn on for the most recent biotech and politics information.
The necessity-to-know this morning
- Daiichi Sankyo and AstraZeneca mentioned the FDA accredited the expanded use of Enhertu, their blockbuster antibody-drug conjugate drug, to deal with sufferers with metastatic, hormone-positive breast most cancers that expresses so-called “low” and “extremely low” ranges of HER2, following hormone remedy. That is the most typical kind of breast most cancers.
Radiopharma firm passes Part 3, however stays mum on specifics
From my colleague Allison DeAngelis: A brand new most cancers therapy developed by ITM Isotope Applied sciences Munich SE has succeeded in a Part 3 trial, setting the stage for a competitor to Novartis’ Lutathera.
ITM introduced right this moment that its experimental radiopharmaceutical remedy ITM-11 led to a statistically vital progression-free survival in sufferers with neuroendocrine tumors which are inoperable. The corporate didn’t give many extra particulars than that, although, and declined to supply extra particular knowledge on affected person response. The corporate plans to current extra of the trial outcomes at a medical assembly, and doubtlessly submit them to the FDA for drug approval later this yr.
The drug is a focused remedy that delivers radioactive isotopes to a marker discovered on neuroendocrine tumors known as SSTR. A lot of these therapies have boomed in recent times, largely as a result of success of Novartis’ medicine Pluvicto — for prostate most cancers — and Lutathera, which can also be for neuroendocrine tumors.
ITM, which is predicated in Germany, largely operated beneath the radar. However the privately held firm has robust roots within the radiopharma discipline: Outdoors of growing medicine, ITM produces and sells radioactive isotopes to corporations like Novartis.
New startup follows Amgen’s weight problems strategy
A brand new startup known as Helicore Biopharma launched right this moment with a deal with growing weight problems medicine that block the GIP hormone, an strategy just like that of Amgen’s experimental therapy MariTide.
The biotech raised $65 million in a Sequence A spherical, led by Versant Ventures and OrbiMed, and with participation from Longitude Capital and Wellington Administration.
Helicore plans to start out Part 1 testing of its lead asset, a monoclonal antibody designed to bind to GIP, within the first quarter. The corporate is aiming for the therapy be dosed much less often than presently out there medicine, probably month-to-month and even quarterly, CEO Gerrit Klaerner mentioned in an interview. And in contrast to different GIP antagonists, Helicore’s drug doesn’t bind to GIP receptors, however as an alternative binds to circulating GIP ligands, an strategy that the Klaerner mentioned will extra successfully block the results of GIP.
The corporate additionally plans to mix its GIP antibody with peptides that focus on different hormones, comparable to GLP-1.
There’s been debate about whether or not weight problems medicine ought to activate or block GIP. There are genetic knowledge suggesting that lack of operate of the GIP receptor is related to decrease physique weight, however on the identical time, medicine comparable to Eli Lilly’s Zepbound — which prompts each GLP-1 and GIP — have been proven to result in substantial weight reduction.
Clarification on one side of Trump’s freeze, however confusion about one other
Final week, the Trump administration instituted a freeze on communications made by well being companies that sowed broad chaos and confusion.
In a current memo to employees, NIH performing director Matthew Memoli clarified what employees can and can’t do. He wrote that workers can begin new work on mission-critical analysis and proceed engaged on ongoing research, however can’t publicly talk about them till the brand new Trump administration lifts the communications freeze. The company additionally expects “extra steerage” this week on the freeze from HHS. Learn extra.
In the meantime, the White Home late yesterday launched a separate order — telling authorities companies to pause grants and loans on a bunch of federal applications.
The inner memo explicitly targets gender-affirming care and international monetary help, however its broad language about “grants and loans” might ensnare plenty of different federal well being and help applications, starting from medical analysis to meals help and doubtlessly even Medicaid, well being care and authorized consultants speculated. Learn extra.
All CDC employees who work with the WHO have been instructed on Sunday evening to right away cease their collaborations and “await additional steerage,” the Related Press reported.
President Trump, in certainly one of his first government orders, started the method of withdrawing the U.S. from WHO, however the order didn’t take fast impact, since leaving the worldwide group requires the approval of Congress and the U.S. remains to be assembly its monetary obligations for the present fiscal yr.
Specialists have been anticipating a sluggish withdrawal, so the sudden stoppage got here as a shock. It comes as well being authorities all over the world are monitoring chook flu outbreaks amongst U.S. livestock and, in comparatively uncommon instances, folks.
As STAT’s Helen Branswell has reported, a U.S. withdrawal from the WHO might have wide-ranging implications for international well being and for home U.S. well being applications. For instance, the WHO runs the method by which the strains that annual flu pictures and Covid vaccines ought to goal are chosen.
A deep dive into RFK Jr.’s plans for vaccine regulation
As RFK Jr. faces affirmation hearings this week on his nomination to steer HHS, my D.C. colleagues carefully analyzed his plans for regulating vaccines.
Although RFK Jr. has insisted that he doesn’t need to take away vaccines and slightly simply needs to ensure they’re secure, he has already sketched out a blueprint that would topic really useful vaccines to renewed scrutiny, redirect analysis, strip authorized protections for vaccine makers, and alter how vaccines are marketed.
This evaluation provides a window into how RFK Jr. might use the levers of energy as the highest U.S. well being official to sow doubt about vaccines at a time when charges of childhood immunizations are already slipping.
Learn extra from STAT’s Rachel Cohrs Zhang and Sarah Owermohle.
Extra reads